The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
The Mainz Severity Score Index: a new instrument for quantifying the Anderson–Fabry disease phenotype, and the response of patients to enzyme replacement therapy
Abstract
Anderson–Fabry disease (AFD) is an X‐linked disorder caused by deficient activity of the lysosomal enzyme α‐galactosidase A. The availability of enzyme replacement therapy (ERT) for this debilitating condition has led to the need for a convenient and sensitive instrument to monitor clinical effects in an individual patient. This study aimed to develop a scoring system – the Mainz Severity Score Index (MSSI) – to measure the severity of AFD and to monitor the clinical course of the disease in response to ERT. Thirty‐nine patients (24 males and 15 females) with AFD were assessed using the MSSI immediately before and 1 year after commencing agalsidase alfa ERT. Control data were obtained from 23 patients in whom AFD was excluded. The MSSI of patients with AFD was significantly higher than that of patients with other severe debilitating diseases. The MSSI indicated that, although more men than women had symptoms classified as severe, overall, the median total severity scores were not significantly different between male and female patients. One year of ERT with agalsidase alfa led, in all patients, to a significant (p < 0.001) reduction in MSSI score (by a median of nine points). This study has shown that the MSSI score may be a useful, specific measure for objectively assessing the severity of AFD and for monitoring ERT‐related treatment effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
急性心筋梗塞の疑いのある17187症例におけるストレプトキナーゼ静脈内投与,アスピリン経口投与,上記2つの併用または無処置の無作偽試験 ISIS-2
Dienstl, F., Backer, G. D., Cairns, J., Pedersen, F., Kala, R., Boissel, J., Schroeder, R., Horgan, J., & Tognoni, G. (1988) · The Lancet · Cited by 2,754
Prevalence of lysosomal storage disorders
Meikle, P. J. (1999) · JAMA · doi:10.1001/jama.281.3.249 · Cited by 2,197
Enzyme Replacement Therapy in Fabry Disease: A Randomized Controlled Trial
Schiffmann, R., Kopp, J. B., Austin III, H. A., Sabnis, S., Moore, D. F., Weibel, T., Balow, J. E., & Brady, R. O. (2001) · JAMA · doi:10.1001/jama.285.21.2743 · Cited by 1,302
MacDermot, K. D., Holmes, A., & Miners, A. H. (2001) · Journal of Medical Genetics · doi:10.1136/jmg.38.11.769 · Cited by 681
Gaucher Disease: Clinical, Laboratory, Radiologic, and Genetic Features of 53 Patients
Zimran, A., Kay, A., Gelbart, T., Garver, P., Thurston, D., Saven, A., & Beutler, E. (1992) · Medicine · doi:10.1097/00005792-199211000-00002 · Cited by 336
PREDICTION OF SEVERITY OF GAUCHER'S DISEASE BY IDENTIFICATION OF MUTATIONS AT DNA LEVEL
Zimran, A., Gross, E., West, C., Sorge, J., Kubitz, M., & Beutler, E. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90536-9 · Cited by 278
Anderson–Fabry disease: Clinical manifestations of disease in female heterozygotes
Whybra, C., Kampmann, C., Willers, I., Davies, J., Winchester, B., Kriegsmann, J., Brühl, K., Gal, A., Bunge, S., & Beck, M. (2001) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1012993305223 · Cited by 276
Self-citation
Cited by
Germain, D. P. (2010) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-5-30 · Cited by 1,198
X‐chromosome inactivation in female patients with Fabry disease
Echevarria, L., Benistan, K., Toussaint, A., Dubourg, O., Hagege, A. A., Eladari, D., Jabbour, F., Beldjord, C., De Mazancourt, P., & Germain, D. P. (2016) · Clinical Genetics · doi:10.1111/cge.12613 · Cited by 424
Natural history of Fabry disease in females in the Fabry Outcome Survey
Deegan, P. B., Baehner, A. F., Barba Romero, M.-Á., Hughes, D. A., Kampmann, C., & Beck, M. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2005.036327 · Cited by 304
Self-citationSchiffmann, R., Ries, M., Timmons, M., Flaherty, J. T., & Brady, R. O. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfi152 · Cited by 269
Self-citationSerum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease
Lenders, M., Stypmann, J., Duning, T., Schmitz, B., Brand, S.-M., & Brand, E. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014121226 · Cited by 133
Metadata
- Authors
- Whybra, C., Kampmann, C., Krummenauer, F., Ries, M., Mengel, E., Miebach, E., Baehner, F., Kim, K., Bajbouj, M., Schwarting, A., Gal, A., & Beck, M.
- Venue
- Clinical Genetics
- Publisher
- Wiley
- Published
- 2004-02-16
- Volume
- 65
- Issue
- 4
- Pages
- 299-307
- ISSN
- 0009-9163 (ISSN-L)
- 1399-0004
- OpenAlex
- W1790440725
- Cited by
- 266
- References
- 7
- FWCI
- 6.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Mainz Severity Score Index: a new instrument for quantifying the Anderson–Fabry disease phenotype, and the response of patients to enzyme replacement therapy. https://app.cochat.ai/papers/10.1111/j.1399-0004.2004.00219.x
- The paper
- Whybra, C., Kampmann, C., Krummenauer, F., Ries, M., Mengel, E., Miebach, E., Baehner, F., Kim, K., Bajbouj, M., Schwarting, A., Gal, A., & Beck, M. (2004). The Mainz Severity Score Index: a new instrument for quantifying the Anderson–Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clinical Genetics. https://doi.org/10.1111/j.1399-0004.2004.00219.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.